Investigative Ophthalmology & Visual Science Cover Image for Volume 58, Issue 8
June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Retinal function improved, assessed with 30-HZ flicker, in patients treated with Aflibercept for neovascular AMD at six months follow-up.
Author Affiliations & Notes
  • Marion Schroeder
    Lund University, Lund, Sweden
  • Ivana Huzevkova
    Lund University, Lund, Sweden
  • Sten Andreasson
    Lund University, Lund, Sweden
  • Monica Loevestam-Adrian
    Lund University, Lund, Sweden
  • Footnotes
    Commercial Relationships   Marion Schroeder, Bayer AB (F); Ivana Huzevkova, None; Sten Andreasson, None; Monica Loevestam-Adrian, Allergan (C), Bayer AB (C), Novartis (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 872. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marion Schroeder, Ivana Huzevkova, Sten Andreasson, Monica Loevestam-Adrian; Retinal function improved, assessed with 30-HZ flicker, in patients treated with Aflibercept for neovascular AMD at six months follow-up.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):872.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate visual outcome and retinal function, assessed with multifocal electroretinography (mfERG) and full-field electroretinography (ffERG), in eyes treated with Aflibercept for neovascular age-related macular degeneration (nAMD).

Methods : This prospective pilot study included 29 eyes of 29 treatment-naïve patients (mean age 79 ±8 years) with nAMD. We examined visual acuity (VA), optical coherence tomography (OCT), mfERG and ffERG prior to intravitreal treatment with Aflibercept and at 6 months follow-up.

Results : We showed significant improvement in mean VA from 65 ±13 to 71 ±17 letters (p=0.001) as well as a decrease of central retinal thickness from 300 ±80 μm to 222 ±37 μm (p<0.001). The decrease in OCT values correlated well to the improvement of VA; r=-0.63, p<0.001. The patients received mean 4.7 ±0.5 injections. FfERG 30-Hz flicker indicated an increase in cone photoreceptor function with a mean amplitude change from 43.9 ±15.0 μV to 49.4 ±18.9 μV (p=0.005). Implicit time was generally prolonged compared to healthy individuals, but was stable from baseline to follow-up; 33.85 ±2.75 ms at baseline and 33.83 ±2.63 ms after 6 months of treatment. No difference was demonstrated in neither MfERG amplitudes nor implicit time from baseline to follow-up.

Conclusions : Retinal function improved, assessed with 30-HZ flicker, in patients treated with Aflibercept for nAMD after six months follow-up. Visual Acuity outcome correlated well to the decrease of central retinal thickness.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×